BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3926660)

  • 21. The establishment of a human myeloma cell line elaborating lambda-light chain protein.
    Niho Y; Shibuya T; Yamasaki K; Kimura N
    Int J Cell Cloning; 1984 May; 2(3):161-72. PubMed ID: 6429256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase.
    Wearne A; Joshua DE; Kronenberg H
    Br J Haematol; 1984 Nov; 58(3):483-9. PubMed ID: 6437432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of RPMI 8226 human myeloma cells by peripheral blood lymphocytes.
    Amano T; Katagiri S; Tominaga N; Oritani K; Tamaki T; Kanayama Y; Yonezawa T; Tarui S
    Acta Haematol; 1992; 87(1-2):37-44. PubMed ID: 1350158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.
    Jackson N; Ling NR; Ball J; Bromidge E; Nathan PD; Franklin IM
    Clin Exp Immunol; 1988 Jun; 72(3):351-6. PubMed ID: 3048803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-B cells in peripheral blood of multiple myeloma patients.
    Pilarski LM; Mant MJ; Ruether BA
    Blood; 1985 Aug; 66(2):416-22. PubMed ID: 3893567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
    Houghton AN; Brooks H; Cote RJ; Taormina MC; Oettgen HF; Old LJ
    J Exp Med; 1983 Jul; 158(1):53-65. PubMed ID: 6864164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in lymphocyte surface immunoglobulins in myeloma and the effect of an RNA-containing plasma factor.
    Chen Y; Bhoopalam N; Yakulis V; Heller P
    Ann Intern Med; 1975 Nov; 83(5):625-31. PubMed ID: 812401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958, and U-1996).
    Jernberg H; Nilsson K; Zech L; Lutz D; Nowotny H; Scheirer W
    Blood; 1987 Jun; 69(6):1605-12. PubMed ID: 3580570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies.
    Sugimoto T; Tatsumi E; Kemshead JT; Helson L; Green AA; Minowada J
    J Natl Cancer Inst; 1984 Jul; 73(1):51-7. PubMed ID: 6610792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
    Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
    Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human bone marrow stroma-dependent myeloma sister cell lines MOLP-6 and MOLP-7 derived from a patient with multiple myeloma.
    Harashima A; Matsuo Y; Nishizaki C; Kozuka T; Fukuda S; Sezaki T; Orita K
    Hum Cell; 2000 Mar; 13(1):43-54. PubMed ID: 10937346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological phenotype of neoplasms involving the B cell in the last step of differentiation.
    San Miguel JF; Caballero MD; Gonzalez M; Zola H; Lopez Borrasca A
    Br J Haematol; 1986 Jan; 62(1):75-83. PubMed ID: 3080019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
    Caligaris-Cappio F; Bergui L; Tesio L; Pizzolo G; Malavasi F; Chilosi M; Campana D; van Camp B; Janossy G
    J Clin Invest; 1985 Sep; 76(3):1243-51. PubMed ID: 2931452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32).
    Ohtsuki T; Yawata Y; Wada H; Sugihara T; Mori M; Namba M
    Br J Haematol; 1989 Oct; 73(2):199-204. PubMed ID: 2479409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia.
    Kubonishi I; Seto M; Shimamura T; Enzan H; Miyoshi I
    Cancer; 1992 Sep; 70(6):1528-35. PubMed ID: 1516003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunophenotyping of classic murine myeloma cell lines used for monoclonal antibody production.
    Rosa EA; Lanza SR; Zanetti CR; Pinto AR
    Hybridoma (Larchmt); 2012 Feb; 31(1):1-6. PubMed ID: 22316479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage.
    Abramson CS; Kersey JH; LeBien TW
    J Immunol; 1981 Jan; 126(1):83-8. PubMed ID: 6969748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous production of IgG lambda and IgA lambda in a clone of myeloma cells.
    Maruyama Y; Sakamaki H; Yahara Y; Onozawa Y; Ozawa N; Shimizu M; Hayashi Y; Kawaguchi K
    Nihon Ketsueki Gakkai Zasshi; 1989 Feb; 52(1):86-92. PubMed ID: 2500824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of one monoclonal immunoglobulin in the presence of another in multiple myeloma. Evidence for benign B-cell neoplasia.
    Keshgegian AA
    Cancer; 1983 Mar; 51(6):1097-100. PubMed ID: 6401598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytogenetic and biological characterization of two new human plasma cell lines.
    Brox LW; Belch A; Pollock E; He XX; De Braekeleer M; Lin CC
    Cancer Genet Cytogenet; 1987 Jul; 27(1):135-44. PubMed ID: 3472643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.